) Ventana Medical Systems announced that it has entered into an
agreement with Germany-based
As per the deal, Roche will collaborate with Merck KGaA's
biopharmaceutical division for the development and
commercialization of a companion diagnostic (CDx) for an
undisclosed target using its proprietary diagnostic assays.
Roche will develop and validate the CDx and ensure its
readiness, availability, and adherence to FDA and other health
authority standards for future clinical trials. Merck KGaA aims to
develop a patient stratifying diagnostic test, which can be used in
multiple cancer indications.
We note that Roche has more than 180 collaboration agreements to
develop and commercialize companion diagnostics globally.
In Jun 2014, Roche entered into a collaboration agreement with
MedImmune, the global biologics research and development arm of
Both the companies are jointly developing a PD-L1 (SP263)
immunohistochemistry assay to enroll patients in clinical trials
for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung
The treatment is based on cancer immunotherapy, which is gaining
a lot of interest in the recent times as pharmaceuticals majors
focus their R&D efforts on the same.
We remind investors that Roche is a specialist in drugs for
oncology, immunology, and infectious diseases. Apart from providing
therapeutic products and services for diverse medical needs, Roche
also focuses on innovative diagnostic solutions for the early
detection and treatment of diseases.
Roche has a broad portfolio of diagnostic tests with more than a
hundred high-quality Elecsys assays for immune testing along with a
new generation of fully automated cobas analyzers for improved
medical decision making, scheduling and efficiency. We are
encouraged by Roche's efforts to further strengthen its Diagnostic
Roche, a large-cap pharma, currently carries a Zacks Rank #3
(Hold). Right now,
) is a better-ranked large-cap pharma with a Zacks Rank #2
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
MERCK KGAA (MKGAF): Get Free Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis
To read this article on Zacks.com click here.